Inhibition of the Class II HMG-CoA reductase of Pseudomonas mevalonii

被引:15
|
作者
Hedl, M [1 ]
Rodwell, VW [1 ]
机构
[1] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA
关键词
HMG-CoA reductase; Class IIHMG-CoA reductase; Pseudomonas mevalonii; isoprenoid biosynthesis; statin drug; Lovastatin;
D O I
10.1110/ps.03597504
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There are two structural classes of HMG-CoA reductase, the third enzyme of the mevalonate pathway of isopentenyl diphosphate biosynthesis-the Class I enzymes of eukaryotes and the Class II enzymes of certain eubacteria. Structural requirements for ligand binding to the Class II HMG-CoA reductase of Pseudomonas mevalonii were investigated. For conversion of mevalonate to HMG-CoA the -CH3, -OH, and -CH2COO- groups on carbon 3 of mevalonate were essential for ligand recognition. The statin drug Lovastatin inhibited both the conversion of HMG-CoA to mevalonate, and the reverse of this reaction. Inhibition was competitive with respect to HMG-CoA or mevalonate and noncompetitive with respect to NADH or NAD(+). K-i values were millimolar. The over 10(4)-fold difference in statin K-i values that distinguishes the two classes of HMG-CoA reductase may result from differences in the specific contacts between the statin and residues present in the Class I enzymes but lacking in a Class II HMG-CoA reductase.
引用
收藏
页码:1693 / 1697
页数:5
相关论文
共 50 条
  • [31] Statin Inhibition of HMG-CoA Reductase by Quantum Biochemistry Computations
    Fulco, U. L.
    Albuquerque, E. L.
    da Silva, L. R.
    29TH SOUTHERN BIOMEDICAL ENGINEERING CONFERENCE (SBEC 2013), 2013, : 159 - +
  • [32] The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation
    Gelosa, Paolo
    Cimino, Mauro
    Pignieri, Alice
    Tremoli, Elena
    Guerrini, Uliano
    Sironi, Luigi
    VASCULAR HEALTH AND RISK MANAGEMENT, 2007, 3 (05) : 567 - 577
  • [33] Combined HMG-COA reductase and prenylation inhibition in treatment of CCM
    Nishimura, Sayoko
    Mishra-Gorur, Ketu
    Park, JinSeok
    Surovtseva, Yulia V.
    Sebti, Said M.
    Levchenko, Andre
    Louvi, Angeliki
    Gunel, Murat
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (21) : 5503 - 5508
  • [34] Predictive Modeling of HMG-CoA Reductase Inhibitory Activity and Design of New HMG-CoA Reductase Inhibitors
    Samizo, Shigeyoshi
    Kaneko, Hiromasa
    ACS OMEGA, 2023, 8 (30): : 27247 - 27255
  • [35] HMG-CoA reductase inhibition has biphasic effects on angiogenesis
    Weis, M
    Heeschen, C
    Cooke, JP
    CIRCULATION, 2001, 104 (17) : 124 - 124
  • [36] Interferon-γ-induced HLA Class II expression on endothelial cells is decreased by inhibition of mTOR and HMG-CoA reductase
    Maenaka, Akihiro
    Kenta, Iwasaki
    Ota, Akinobu
    Miwa, Yuko
    Ohashi, Wataru
    Horimi, Kosei
    Matsuoka, Yutaka
    Ohnishi, Masafumi
    Uchida, Kazuharu
    Kobayashi, Takaaki
    FEBS OPEN BIO, 2020, 10 (05): : 927 - 936
  • [37] Various HMG-CoA reductase inhibitors
    Thiery, J
    Seidel, D
    INTERNIST, 1999, 40 (01): : 113 - 114
  • [38] DRUGS INHIBITING HMG-COA REDUCTASE
    ENDO, A
    PHARMACOLOGY & THERAPEUTICS, 1985, 31 (03) : 257 - 267
  • [39] HMG-CoA reductase inhibitors and the kidney
    Vito M. Campese
    Bassel Hadaya
    Josephine Chiu
    Current Hypertension Reports, 2005, 7 : 337 - 342
  • [40] HMG-CoA reductase inhibitors and apoptosis
    Senatore, M
    Buemi, M
    NEPHRON, 1999, 81 (04): : 439 - 440